Xinran Cai

Xinran Cai

Auto-generated profile, based on publicly available information

Xinran Cai

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2021 in Science Advances
Verified
Journal Article
Open access
YXYue Xi
Yue Xi
YLYanping Li
Yanping Li
PXPengfei Xu
Pengfei Xu
SLSihan Li
Sihan Li
ZLZhengsheng Liu
Zhengsheng Liu
WXWen Xie
Wen Xie
Pirfenidone inhibits HSC activation and liver fibrosis by targeting glutaredoxin-1 and reducing Smad3 glutathionylation.

25 September 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
HTHung-Chun Tung
Hung-Chun Tung
JKJong-Won Kim
Jong-Won Kim
JZJunjie Zhu
Junjie Zhu
SLSihan Li
Sihan Li
JYJiong Yan
Jiong Yan
WXWen Xie
Wen Xie
Activation of extracellular matrix–producing hepatic stellate cells (HSCs) is a key event in liver fibrogenesis. We showed that the expression of the heme-thiolate monooxygenase cytochrome P450 1B1 (CYP1B1) was elevated in human and mouse fibrotic livers and activated HSCs. Systemic or HSC-specific ablation and pharmacological inhibition of CYP1B1 attenuated HSC activation and protected male but not female mice from thioacetamide (TAA)–, carbon tetrachloride (CCl 4 )–, or bile duct ligation (BDL)–induced liver fibrosis. Metabolomic analysis revealed an increase in the disaccharide trehalose in CYP1B1-deficient HSCs resulting from intestinal suppression of the trehalose-metabolizing enzyme trehalase, whose gene we found to be a target of RARα. Trehalose or its hydrolysis-resistant derivative lactotrehalose exhibited potent antifibrotic activity in vitro and in vivo by functioning as an HSC-specific autophagy inhibitor, which may account for the antifibrotic effect of CYP1B1 inhibition. Our study thus reveals an endobiotic function of CYP1B1 in liver fibrosis in males, mediated by liver-intestine cross-talk and trehalose. At the translational level, pharmacological inhibition of CYP1B1 or the use of trehalose/lactotrehalose may represent therapeutic strategies for liver fibrosis.

24 October 2024 in Hepatology
Verified
Journal Article
Closed access
JKJong-Won Kim
Jong-Won Kim
HTHung-Chun Tung
Hung-Chun Tung
MKMengyun Ke
Mengyun Ke
PXPengfei Xu
Pengfei Xu
XCXinran Cai
Xinran Cai
WXWen Xie
Wen Xie
Background and Aims: Liver fibrosis is characterized by the progressive scarring of liver tissue. Oxidative stress is a critical causal factor of HSC activation and subsequent liver fibrogenesis, but the mechanism is not fully understood. Cysteine sulfinic acid (Cys-SO2H), a modification of reactive cysteine residues, is a unique form of oxidative response that alters the structure and function of proteins. Sulfiredoxin-1 (SRXN1) is responsible for the ATP-dependent reduction of the Cys-SO2H to sulfenic acid (Cys-SOH). Approach and Results: We found that the expression of SRXN1 was increased in activated HSCs and in human and mouse fibrotic livers. HSC-specific ablation of Srxn1 or pharmacological inhibition of Srxn1 exacerbated HSC activation and sensitized mice to liver fibrosis. Mechanistically, SRXN1 inhibited HSC activation by desulfinylating the phosphatase protein tyrosine phosphatase nonreceptor type 12 (PTPN12), which enhanced its phosphatase activity and protein stability, leading to decreased tyrosine phosphorylation and reduced activation of the profibrotic inflammasome protein NLRP3 (nucleotide-binding domain, leucine-rich–containing family, pyrin domain–containing-3). The antifibrotic effect of SRXN1 was abolished when NLRP3 was inhibited. In contrast, overexpression of PTPN12 attenuated NLRP3 activation, and this effect was further amplified by the C164A S-sulfinylation–resistant mutant of PTPN12. Conclusions: Our findings have uncovered an important role of SRXN1 and protein S-sulfinylation in HSC activation and liver fibrosis. The SRXN1-PTPN12-NLRP3 axis represents potential therapeutic targets for liver fibrosis.